Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2019-08-14 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Calquence granted US Breakthrough Therapy Designat
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 9922I' and concludes with information about RNS, the news service of the London Stock Exchange, which is approved by the Financial Conduct Authority (FCA). The content is a press release announcing that the US FDA granted Breakthrough Therapy Designation (BTD) for the drug Calquence for CLL treatment, based on Phase III trial results. This type of announcement, which disseminates material, non-financial news to the market via an official regulatory news service, fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (like 10-K, ER, or IR), nor is it a management change (MANG) or dividend notice (DIV). Since it is a formal announcement disseminated through the RNS system, RNS is the most appropriate classification.
2019-08-14 English
TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL
Regulatory Filings
2019-08-09 English
Amendment: Tagrisso significantly improves overall
Legal Proceedings Report Classification · 99% confidence The document explicitly starts with an 'RNS Number' and is identified as an announcement from AstraZeneca PLC dated 09 August 2019. It details a correction to a previous announcement regarding clinical trial results (Tagrisso in NSCLC). The presence of the RNS Number, the reference to the London Stock Exchange, and the nature of the content (a specific, timely corporate update/correction) strongly indicate this is a regulatory filing disseminated via the RNS system. Since it is a general regulatory announcement that doesn't fit perfectly into specific categories like ER, DIV, or DIRS, the most appropriate classification is the general regulatory filing category.
2019-08-09 English
Tagrisso significantly improves overall survival
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 5270I' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This strongly indicates a regulatory announcement disseminated via the RNS system. The content is a press release announcing positive clinical trial results (Phase III FLAURA trial for Tagrisso), which is a type of material news that must be disclosed promptly to the market. While it contains detailed medical/scientific information, its primary function here is the immediate public disclosure of a material event via the official regulatory channel, fitting the definition of a general regulatory announcement or filing that doesn't fit a more specific financial report category like 10-K or ER. Given the explicit RNS identification, RNS is the most appropriate classification.
2019-08-09 English
LYNPARZA PHASE III PROFOUND TRIAL IN HRR*
Regulatory Filings
2019-08-07 English
Lynparza Phase III PROfound trial in HRR*
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 2080I' and is dated '07 August 2019'. It announces positive clinical trial results for a drug (Lynparza) and includes extensive details about the trial, the drug, and the companies involved. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a general regulatory news service announcement, which fits the definition of Regulatory Filings (RNS), as it is a broad announcement of material information released via the official regulatory channel, rather than a specific financial report like 10-K, ER, or IR.
2019-08-07 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.